Triple

T1168574
Position Surface form Disambiguated ID Type / Status
Subject Eli Lilly and Company E24856 entity
Predicate notableProduct P1448 FINISHED
Object Alimta
Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
 E133650 NE FINISHED

How this triple was built (4 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Alimta | Statement: [Eli Lilly and Company, notableProduct, Alimta]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07 
Target entity: Alimta
Context triple: [Eli Lilly and Company, notableProduct, Alimta]
  • A. Avastin
    Avastin is a widely used cancer drug (bevacizumab) that inhibits angiogenesis by targeting vascular endothelial growth factor (VEGF).
  • B. Rituxan
    Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
  • C. Herceptin
    Herceptin is a targeted monoclonal antibody drug used primarily to treat HER2-positive breast cancer by blocking the HER2 receptor on cancer cells.
  • D. Tecentriq
    Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
  • E. Imbruvica
    Imbruvica is a targeted cancer therapy (a Bruton's tyrosine kinase inhibitor) used primarily to treat certain types of blood cancers such as mantle cell lymphoma and chronic lymphocytic leukemia.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg Description generation gpt-5.1
Instruction
Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: Alimta
Triple: [Eli Lilly and Company, notableProduct, Alimta]
Generated description
Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07 
Target entity: Alimta
Target entity description: Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
  • A. Avastin
    Avastin is a widely used cancer drug (bevacizumab) that inhibits angiogenesis by targeting vascular endothelial growth factor (VEGF).
  • B. Rituxan
    Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
  • C. Herceptin
    Herceptin is a targeted monoclonal antibody drug used primarily to treat HER2-positive breast cancer by blocking the HER2 receptor on cancer cells.
  • D. Tecentriq
    Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
  • E. Imbruvica
    Imbruvica is a targeted cancer therapy (a Bruton's tyrosine kinase inhibitor) used primarily to treat certain types of blood cancers such as mantle cell lymphoma and chronic lymphocytic leukemia.
  • F. None of above. chosen

Provenance (5 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69a494082a7c819095004f423f294a64 completed March 1, 2026, 7:31 p.m.
NER Named-entity recognition batch_69a4bccef84481908864e819884af86c completed March 1, 2026, 10:25 p.m.
NED1 Entity disambiguation (via context triple) batch_69ac668562788190ac5f8d081a46b2ee completed March 7, 2026, 5:55 p.m.
NEDg Description generation batch_69ac67a07f28819096fcd7b767e07a63 completed March 7, 2026, 6 p.m.
NED2 Entity disambiguation (via description) batch_69ac6826ef4c81909fc077bfba22b16f completed March 7, 2026, 6:02 p.m.
Created at: March 1, 2026, 7:45 p.m.